Pharmacotherapy 1986-01-01

Combination dihydroergotamine mesylate and heparin sodium with lidocaine HCl. Pharmacokinetics, mechanism of action, clinical efficacy, and adverse effects.

J A Barone, J J Raia, D B Levy

Index: Pharmacotherapy 6(4 Pt 2) , 3S-11S, (1986)

Full Text: HTML

Abstract

Dihydroergotamine(DHE)-heparin combination offers a unique treatment modality for the prevention of deep vein thrombosis. The combination appears to affect all 3 limbs of Virchow's triad: hypercoagulability, venous stasis, and endothelial damage. In most efficacy studies, data indicated that the combination of DHE 0.5 mg and heparin 5000 IU was superior to low-dose heparin alone. Even when the efficacy of DHE-heparin was the same as that of heparin alone, the use of the combination allowed for a decrease in the heparin dose required.

Related Compounds

  • Dihydro Ergotamin...

Related Articles:

Role of 5-HT1B/1Dreceptors in the reduction of formalin-induced nociception and secondary allodynia/hyperalgesia produced by antimigraine drugs in rats

2013-06-13

[Life Sci. 92(22) , 1046-54, (2013)]

Structural basis for molecular recognition at serotonin receptors.

2013-05-03

[Science 340(6132) , 610-4, (2013)]

Intrapulmonary and intravenous administrations of dihydroergotamine mesylate have similar cardiovascular effects in the conscious dog.

2008-07-01

[Br. J. Pharmacol. 154(6) , 1254-65, (2008)]

Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma.

2002-03-05

[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 768(2) , 267-75, (2002)]

MT 300--POZEN: dihydroergotamine mesylate injection.

2003-01-01

[Drugs R. D. 4(6) , 376-7, (2003)]

More Articles...